Laura Huppert, MD

Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF

Cancer Center Program Membership

Breast Oncology

Research Summary

Dr. Laura Huppert is an oncologist who cares for patients with all stages of breast cancer.

Huppert's research focuses on designing and conducting clinical trials to evaluate new cancer treatments, including ways to combine therapies so as to improve outcomes. She also studies metastatic breast cancer (that has spread to other body parts), including cancer that has reached the brain and leptomeninges (membranes surrounding the brain and spinal cord), and works to translate findings from the lab into care provided to patients.

Huppert earned her medical degree at Harvard Medical School. She completed a residency in internal medicine and a fellowship in hematology and oncology at UCSF. She is a member of the American Society of Clinical Oncology (ASCO) and has received an ASCO Merit Award as well as grants from the California Breast Cancer Research Program.


  • Harvard College B.A. 09/2006 05/2010 Molecular and Cellular Biology
  • Harvard Medical School M.D. 09/2011 05/2015 Medicine
  • University of California, San Francisco Residency 07/2015 06/2018 Internal Medicine
  • University of California, San Francisco Fellowship 07/2019 06/2022 Medical Hematology and Oncology

Honors & Awards

  • 2022 ASCO Merit Award
  • 2021 UCSF Internal Medicine Residency Fellow of the Year Award
  • 2021 UCSF Graduate Medical Education Excellence and Innovation Award
  • 2020 UCSF Hematology/Oncology Clinical Fellow of the Year Award  

Selected Publications

  1. Huppert LA, Rugo HS. Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer? Clin Cancer Res. 2023 Oct 02.  View on PubMed
  2. Cecil K, Huppert L, Mukhtar R, Dibble EH, O'Brien SR, Ulaner GA, Lawhn-Heath C. Metabolic Positron Emission Tomography in Breast Cancer. PET Clin. 2023 Oct; 18(4):473-485.  View on PubMed
  3. Tasoulis MK, Huppert LA. Invited Commentary: Can We De-Escalate More Than 1 Breast Cancer Treatment Modality at the Same Time? J Am Coll Surg. 2023 08 01; 237(2):256-258.  View on PubMed
  4. Im KW, Huppert LA, Malevanchik L, Rugo HS, Combes AJ, Campbell MJ, Krummel MF, Melisko ME. High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease. NPJ Breast Cancer. 2023 Apr 07; 9(1):22.  View on PubMed
  5. Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N. Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression. bioRxiv. 2023 Mar 29.  View on PubMed
  6. Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023 Mar 20.  View on PubMed
  7. Jacob SL, Huppert LA, Rugo HS. Role of Immunotherapy in Breast Cancer. JCO Oncol Pract. 2023 04; 19(4):167-179.  View on PubMed
  8. Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, Melisko ME, Rugo HS, Behr S, Chien AJ. Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast Cancer Res Treat. 2022 Nov 02.  View on PubMed
  9. Huppert LA, Daud AI. Intratumoral therapies and in-situ vaccination for melanoma. Hum Vaccin Immunother. 2022 05 31; 18(3):1890512.  View on PubMed
  10. Huppert LA, Gumusay O, Rugo HS. Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221086916.  View on PubMed
  11. Gumusay O, Huppert LA, Behr SC, Rugo HS. The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases. Breast. 2022 Jun; 63:149-156.  View on PubMed
  12. Isaza E, Huppert LA, Lai AR, Brondfield S. Tumor Fever Due to Metastatic Esophageal Squamous Cell Carcinoma. Am J Med. 2022 08; 135(8):e294-e295.  View on PubMed
  13. Huppert LA, Babik JM. Development and Evaluation of a Five-Component Toolkit for Internal Medicine Residents Applying for Subspecialty Fellowships. MedEdPORTAL. 2022; 18:11228.  View on PubMed
  14. Huppert LA, Hsu G, Elnachef N, Flint L, Frank JA, Gensler LS, Hsiao EC, Khanna RR, Qasim A, Schwartz BS, Widera E, Zapata C, Babik JM. A single center evaluation of applicant experiences in virtual interviews across eight internal medicine subspecialty fellowship programs. Med Educ Online. 2021 Dec; 26(1):1946237.  View on PubMed
  15. Huppert LA, Mariotti V, Chien AJ, Soliman HH. Emerging immunotherapeutic strategies for the treatment of breast cancer. Breast Cancer Res Treat. 2022 Jan; 191(2):243-255.  View on PubMed
  16. Roberts HJ, Huppert LA. Letter to the Editor: The Effect of COVID-19 on the Orthopaedic Surgery Residency Application Process. J Am Acad Orthop Surg. 2023 02 01; 31(3):e130-e132.  View on PubMed
  17. Huppert LA, Green MD, Kim L, Chow C, Leyfman Y, Daud AI, Lee JC. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol Immunol. 2022 01; 19(1):33-45.  View on PubMed
  18. Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. The Liver-Immunity Nexus and Cancer Immunotherapy. Clin Cancer Res. 2022 01 01; 28(1):5-12.  View on PubMed
  19. Huppert LA, Daud AI. Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. J Clin Oncol. 2021 08 20; 39(24):2637-2639.  View on PubMed
  20. Rugo HS, Huppert L. Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3275-3277.  View on PubMed

Go to UCSF Profiles, powered by CTSI